Document is current

Article History

Received: 6 November 2024

Accepted: 10 June 2025

First Online: 20 June 2025

Competing interests

: J.A.: Pfizer Grant/Contract, Travel, Other, consulting; Lilly Grant/Contract, Travel, Other, consulting; Novartis Other, consulting; Roche Grant/Contract, Travel, Other, Consulting; Amgen Grant/Contract, Travel, Other, consulting; MSD Grant/Contract, Travel, Other, Consulting; Daiichi Sankyo Grant/Contract, Travel, Other, consulting. A.G.P.: None. C.L.A., Pfizer Grant/Contract; Lilly Grant/Contract; Radius Grant/Contract; Bayer Grant/Contract; Takeda Grant/Contract; Provista Stock Option; Puma Biotechnology Other, Scientific advisor; Novartis Other, Scientific advisor; TAIHO Oncology Other, Scientific advisor; Daiichi Sankyo Scientific advisor; Merck Scientific advisor; AstraZeneca Other, Scientific advisor; OrigiMed Other, Scientific advisor; Immunomedics Other, Scientific advisor; Athenex Other, Scientific advisor; Arvinas Other, Scientific advisor. M.B.: Pfizer Travel, Other, Consulting, honoraria; Novartis Other, consulting, honoraria; Lilly Other, consulting, honoraria; Stemline-Menarini Other, consulting. F.R.: Roche Other, consulting; BMS Other, consulting; AstraZeneca consulting; MSD Other, consulting; Merck Other, consulting; Novartis Other, consulting; Pierre Fabre Other, consulting; InCyte Other, consulting; Abbvie Other, consulting. A.G.: None. B.B.: Amgen Other, honoraria; AstraZeneca Other, honoraria; Biocartis Other, honoraria; Janssen Other, honoraria. Merck-Serono Other, honoraria; Novartis Other, honoraria; Qiagen Other, honoraria; Hoffman-La Roche Other, honoraria. ThermoFisher Grant/Contract, Other, honoraria; Pfizer Other, honoraria; BMS Other, honoraria; Roche Diagnostics Grant/Contract; Roche Farma Grant/Contract. V.S.: Novartis Grant/Contract; Genetech Grant/Contract; AstraZeneca Grant/Contract; P.G.: None. J.G.: None. E.S.: None. M.M.: None. J.R.-M.: None. L.M.: None. J.P.-G.: Roche Travel, Other, Consulting; Eiasi Other, Consulting Daichii Sankyo Other, Consulting; AstraZeneca Other, Consulting; Gilead Other, Consulting; MSD Other, Consulting; Seagen Other, Consulting. J.C.: ARIAD Grant/Contract; AstraZeneca Grant/Contract, Other, Consulting; Baxalta GMBH/Servier Affaires Grant/Contract; Bayer Grant/Contract; Eisai Grant/Contract, Travel, Other, honoraria; Guardant Health Grant/Contract; MSD Grant/Contract, Other, honoraria, consulting; Pfizer Grant/Contract, Travel, Other, honoraria, consulting; Puma Grant/Contract; Roche Grant/Contract, Travel, Other, honoraria, consulting; Piqur Grant/Contract; Novartis Travel, Other, honoraria; Celgene Other, consulting, honoraria; Samsung Other, honoraria; Daiichi Sankyo Travel, Other, honoraria, consulting; Eli Lilly Other, honoraria; Reveal Genomics Other, Consulting; Seagen Other, Consulting; Menarini Other, Consulting; Leuko Stock, Other, Consulting. A.L.-C.: Roche Grant/Contract, Travel, Other, honoraria, consulting; AstraZeneca Grant/Contract, Other, consulting; Seagen Other, consulting; Daiichi Sankyo Travel, Other, consulting, honoraria; Eli Lilly Other, consulting, honoraria; MSD Grant/Contract, Other, consulting; GSK Other, consulting; Gilead Travel, Other, consulting; Menarini Other, consulting; ExactSciences Other, Consulting; Novartis Travel, Other, consulting, honoraria; Agendia Other, consulting; Pfizer Grant/Contract, Travel, Other, consulting, honoraria; F Hoffman La Roche Grant/Contract; Guardant Health Grant/Contract.